A detailed history of Schonfeld Strategic Advisors LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 20,737 shares of ITCI stock, worth $1.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,737
Previous 134,454 84.58%
Holding current value
$1.72 Million
Previous $9.21 Million 83.54%
% of portfolio
0.01%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $7.73 Million - $9.19 Million
-113,717 Reduced 84.58%
20,737 $1.52 Million
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $7.13 Million - $8.79 Million
110,036 Added 450.63%
134,454 $9.21 Million
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $9.12 Million - $10.7 Million
-141,703 Reduced 85.3%
24,418 $1.69 Million
Q4 2023

Feb 14, 2024

BUY
$46.37 - $73.65 $7.7 Million - $12.2 Million
166,121 New
166,121 $11.9 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $1.33 Million - $1.87 Million
-31,130 Reduced 49.26%
32,071 $1.49 Million
Q2 2022

Aug 15, 2022

SELL
$43.0 - $65.64 $1.49 Million - $2.28 Million
-34,724 Reduced 35.46%
63,201 $3.61 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $2.95 Million - $4.73 Million
76,210 Added 350.96%
97,925 $5.99 Million
Q4 2021

Feb 14, 2022

BUY
$35.2 - $53.42 $403,884 - $612,941
11,474 Added 112.04%
21,715 $1.14 Million
Q2 2021

Aug 16, 2021

BUY
$29.3 - $44.5 $300,061 - $455,724
10,241 New
10,241 $418,000
Q4 2017

Feb 14, 2018

SELL
$14.27 - $16.79 $1.88 Million - $2.22 Million
-131,980 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $1.42 Million - $2.92 Million
131,980
131,980 $2.08 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.